By Sasa Rajsic, Benedikt Treml, Dragana Jadzic, Robert
Breitkopf, Christoph Oberleitner, Marina Popovic Krneta and Zoran Bukumiric
Annals of
Intensive Care volume 12,
Article number: 93 (2022)
Background
Venoarterial extracorporeal membrane oxygenation (va-ECMO)
is an advanced life support for critically ill patients with refractory
cardiogenic shock. This temporary support bridges time for recovery, permanent
assist, or transplantation in patients with high risk of mortality. However,
the benefit of this modality is still subject of discussion and despite the
continuous development of critical care medicine, severe cardiogenic shock
remains associated with high mortality. Therefore, this work aims to analyze
the current literature regarding in-hospital mortality and complication rates
of va-ECMO in patients with cardiogenic shock.
Methods
We conducted a systematic review and meta-analysis of the
most recent literature to analyze the outcomes of va-ECMO support. Using the
PRISMA guidelines, Medline (PubMed) and Scopus (Elsevier) databases were
systematically searched up to May 2022. Meta-analytic pooled estimation of
publications variables was performed using a weighted random effects model for
study size.
Results
Thirty-two studies comprising 12756 patients were included
in the final analysis. Between 1994 and 2019, 62% (pooled estimate, 8493/12756)
of patients died in the hospital. More than one-third of patients died during
ECMO support. The most frequent complications were renal failure (51%,
693/1351) with the need for renal replacement therapy (44%, 4879/11186) and
bleeding (49%, 1971/4523), bearing the potential for permanent injury or death.
Univariate meta-regression analyses identified age over 60 years, shorter
ECMO duration and presence of infection as variables associated with
in-hospital mortality, while the studies reporting a higher incidence of
cannulation site bleeding were unexpectedly associated with a reduced
in-hospital mortality.
Conclusions
Extracorporeal membrane oxygenation is an invasive life
support with a high risk of complications. We identified a pooled in-hospital
mortality of 62% with patient age, infection and ECMO support duration being
associated with a higher mortality. Protocols and techniques must be developed
to reduce the rate of adverse events. Finally, randomized trials are necessary
to demonstrate the effectiveness of va-ECMO in cardiogenic shock.
No comments:
Post a Comment